Enzastaurin: A lesson in drug development

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Enzastaurin is an orally administered drug targeting protein kinase Cβ (PKCβ), implicated in cancer signaling pathways like AKT and MAPK.
• Preclinical studies indicated potential in preventing angiogenesis, inhibiting proliferation, and inducing apoptosis, with limited cytotoxicity in early trials.

Purpose of the Study:

• To review the development of enzastaurin from initial drug design through clinical testing.
• To analyze the challenges in translating preclinical findings to clinical efficacy for anticancer therapeutics.

Main Methods:

• Exploration of target identification, validation, and preclinical assessment of enzastaurin.
• Review of clinical trial data from Phase I, II, and III, focusing on efficacy and safety.

Main Results:

• Enzastaurin demonstrated encouraging preclinical results but exhibited poor efficacy in Phase II and III clinical trials, both as a single agent and in combination therapies.
• Limited cytotoxicity was observed in Phase I trials, but overall clinical efficacy was insufficient for approval.

Conclusions:

• The failure of enzastaurin highlights significant challenges in anticancer drug development, including poor preclinical-to-clinical translation, inadequate endpoint analysis, and insufficient patient stratification.
• Issues such as limited biomarker analysis and suboptimal Phase I trial standards contributed to the lack of approval for enzastaurin as an anticancer therapeutic.